Crystal forms of pyridopyrazole compounds and preparation method therefor
Provided are crystal forms of compounds represented by formula(II)-formula (VIII) and formula (I)-formula (VIII-1), a preparation method therefor and an application of the compounds and crystal forms in the preparation of a drug for treating a related disease.
1 . A crystal form A of the compound of Formula (I),
wherein the X-ray powder diffraction pattern of the crystal form A has characteristic diffraction peaks at the 2θ angles comprising: 15.51±0.20°, 16.30±0.20°, 19.16±0.20°, 21.69±0.20° and 24.63±0.20°.
2 . The crystal form A according to claim 1 , wherein the X-ray powder diffraction pattern of the crystal form A has characteristic diffraction peaks at the 20 angles of: 14.88 t 0.20°, 15.51±0.20°, 16.30±0.20°, 18.49±0.20°, 19.16±0.20°, 19.70±0.20°, 21.69±0.20° and 24.63±0.20°.
3 . The crystal form A according to claim 2 , wherein the X-ray powder diffraction pattern of the crystal form A has characteristic diffraction peaks at the 20 angles of: 7.79±0.20°, 9.58±0.20°, 12.61±0.20°, 14.88±0.20°, 15.51±0.20°, 16.30±0.20°, 18.49±0.20°, 19.16±0.20°, 19.70±0.20°, 21.69 t 0.20° and 24.63±0.20°.
4 . The crystal form A according to claim 1 , wherein the XRPD pattern of the crystal form A has characteristic diffraction peaks at the 2θ angles of:
No.
2θ angle (°)
1
3.29
2
6.19
3
7.79
4
9.21
5
9.58
6
10.32
7
12.61
8
14.88
9
15.10
10
15.51
11
16.30
12
16.60
13
17.65
14
18.49
15
19.16
16
19.70
17
20.03
18
20.45
19
21.69
20
22.24
21
22.83
22
23.38
23
24.63
24
25.29
25
25.76
26
26.58
27
27.70
28
28.34
29
29.06
30
31.71
31
32.97
32
33.49.
5 . The crystal form A according to claim 1 , wherein the differential scanning calorimetry curve of the crystal form A has a starting point of an endothermic peak at 188.7±2° C.
6 . The crystal form A according to claim 1 , wherein the thermogravimetric analysis curve of the crystal form A shows a weight loss of 1.20% at 180.0±3° C.
7 . The crystal form A according to claim 2 , wherein the differential scanning calorimetry curve of the crystal form A has a starting point of an endothermic peak at 188.7±2° C.
8 . The crystal form A according to claim 3 , wherein the differential scanning calorimetry curve of the crystal form A has a starting point of an endothermic peak at 188.7±2° C.
9 . The crystal form A according to claim 2 , wherein the thermogravimetric analysis curve of the crystal form A shows a weight loss of 1.20% at 180.0±3° C.
10 . The crystal form A according to claim 3 , wherein the thermogravimetric analysis curve of the crystal form A shows a weight loss of 1.20% at 180.0±3° C.
11 . A method of treating solid tumor in a subject in need thereof, comprising administering an effective amount of the crystal form A of the compound of Formula (I) according to claim 1 to the subject.
12 . The method according to claim 11 , wherein the solid tumor is an RET kinase-associated solid tumor.